Sclerostin and Bone Metabolism Markers in Hyperthyroidism before Treatment and Interrelations between Them
Sclerostin is a glycoprotein that is produced by osteocytes and reduces the formation of bones by inhibiting Wnt signal pathway. Thyroid hormones are related with Wnt signal pathway and it has been reported that the increasing thyroid hormones in hyperthyroidism fasten the epiphysis maturation in childhood, increase the risk of bone fractures by stimulating the bone loss in adults.
The aim of this study is examining the sclerostin serum levels, the relation between sclerostin and thyroid hormones and the biochemical markers of bone metabolism in patients with hyperthyroidism whose treatments have not started yet.
No difference was found in the serum sclerostin levels between the hyperthyroidism group and the control group (p=0.452). The serum osteocalcin levels and 24-hour urinary phosphorus excretion were found to be higher in the hyperthyroid group than the control group (p<0.001, p=0.009). A positive correlation (p<0.001) was determined between the sclerostin and bone Alkaline phosphatase levels; a negative correlation (p<0.05) between the osteocalcin and thyroid stimulating hormone (TSH); a positive correlation (p<0.001, p<0.001) between the osteocalcin and thyroid hormones (FT3 , FT4); and a positive correlation (p<0.001) between the deoxypyridinoline and hydroxyproline. No correlation was determined between sclerostin and TSH, FT3, FT4 (p>0.05). We are considering that a long-term study that covers the pre-treatment and post-treatment periods in hyperthyroidism patients, and the search during destruction and construction periods of the skeleton mineralization would be more enlightening; and the assessment of the synthesis of the sclerostin in bone tissue and in the serum level might show differences.
Akalın A, Colak O, Alatas O, Efe B (2002) Bone remodelling markers and serum cytokines in patients with hyperthyroidism. Clin Endocrinol (Oxf) 57:125-129
Barsal G, Taneli F, Atay A, Hekimsoy Z, Erciyas F (2004) Serum osteocalcin levels in hyperthyroidism before and after antithyroid therapy. Tohoku J Exp Med. 203:183-188.
Bassett JH, O'Shea PJ, Sriskantharajah S, Rabier B, Boyde A, Howell PGT et al. (2007) Thyroid hormone excess rather than thyrotropin deficiency induces osteoporosis in hyperthyroidism. Mol Endocrinol 21:1095- 1107
Ben-Shlomo A, Hagag P, Evans S, Weiss M (2001) Early postmenopausal bone loss in hyperthyroidism. Maturitas The European menapouse Journal 39:19-27
Bergman I & Loxley R (1963) Two Improved and Simplified Methods for the Spectrophotometric Determination of Hydroxyproline. Anal Chem 35:1961–1965.
Calvo MS, Eyre DR, Gundberg CM (1996) Biological markers of bone turnover. Endocr Rev 17: 333-368.
Cardoso LF, Maciel LMZ, de Paula FJA (2014) The multiple effects of thyroid disorders on bone and mineral metabolism. Arq Bras Endocrinol Metab 58:452-463
Krishnan V, Bryant HU, Macdougald OA (2006) Regulation of bone mass by Wnt signaling. J Clin Invest 116:1202-1209.
Lee AJ, Hodges S, Eastell R (2000) Measurment of osteocalcin. Ann Clin Biochem 37:432- 446
Lin C, Jiang X, Dai Z, Guo X, Weng T, Wang J, et al (2009) Sclerostin mediates bone response to mechanical unloading through antagonizing Wnt/ β-catenin signaling. J Bone Miner Res 24:1651-1661
Mosekilde L, Melsen F, Bagger JP, Myhre-Jensen O, Schwartz Sorensen N (1977) Bone changes in hyperthyroidism: interrelationships between bone morphometry, thyroid function and calcium-phosphorus metabolism. Acta Endocrinol 85:515-525
Nagasaka S, Sugimoto H, Nakamura T, Kusaka I, Fujisawa G, Sakuma N et al (1997) Antithyroid therapy improves bony manifestations and bone metabolic markers in patients with Graves' thyrotoxicosis. Clin Endocrinol 47:215-221
Ogilvy-Stuart AL (2002) Neonatal thyroid disorders. Arch Dis Child Fetal Neonatal Ed 87:165-171
Ohıshı TK, Kushıda K, Takahashı M, Kawana K, Yagı K, Kawakamı K et al (1994) Urinary Bone Resorption Markers in Patients with Metabolic Bone Disorders. Bone 15:15-20
O’Shea P J, Kim DW, Logan JG, Davis S, Walker RL, Meltzer PS et al (2012) Advanced Bone Formation in Mice with a Dominant-negative Mutation in the Thyroid Hormone Receptor β Gene due to Activation of Wnt/β-Catenin Protein Signaling. The Journal of Bıologıcal Chemıstry 287: 17812–17822
Pantazi H, Papapetrou PD (2000) Changes in parameters of bone and mineral metabolism during therapy for hyperthyroidism. J Clin Endocrinol Metab 85:1099-1106
Poole KE, van Bezooijen RL, Loveridge N, Hamersma H, Papapoulos SE, Löwik CW et al (2005) Sclerostin is a delayed secreted product of osteocytes that inhibits bone formation. Faseb Journal doi: 10.1096/fj.05-4221fje
Sabuncu T, Aksoy N, Arıkan E, Ugur B, Tasan E, Hatemi H (2001) Early changes in parameters of bone and mineral metabolism during therapy for hyper- and hypothyroidism. Endocr Res 27:203-213
Schouten BJ1, Prickett TC, Hunt PJ, Richards AM, Geffner ME, Olney RC et al (2012) C-type natriuretic peptide forms in adult hyperthyroidism: correlation with thyroid hormones and markers of bone turnover. Clin Endocrinol 76:790-796
Skowrońska-Jóźwiak E, Krawczyk-Rusiecka K, Lewandowskji KC, Adamczewski Z, Lewinski A (2012) Successful treatment of thyrotoxicosis is accompanied by a decrease in serum sclerostin levels. BMC Thyroid Research 5:14
Skowrońska-Jozwiak E, Lewandowski KC, Adamczewski Z, Krawczyk-Rusiecka K, Lewiński A (2015) Mechanisms of Normalisation of Bone Metabolism during Recovery from Hyperthyroidism: Potential Role for Sclerostin and Parathyroid Hormone. Int J Endocrinol Article ID 948384 page 5
Tsourdi E, Rijntjes E, Köhrle J, Hofbauer LC, Rauner M (2015) Hyperthyroidism and Hypothyroidism in Male Mice and Their Effects on Bone Mass, Bone Turnover, and the Wnt Inhibitors Sclerostin and Dickkopf-1. Endocrinology 156:3517-3527
Van Bezooijen RL, Roelen BA, Visser A, van der Wee-Pals L, de Wilt E, Karperien M et al. (2004) Sclerostin is an osteocyte-expressed negative regulator of bone formation, but not a classical BMP antagonist. J Exp Med 199:805-814
Van Bezooijen RL, Svensson JP, Eefting D, Visser A, van der Horst G, Karperien M et al (2007) Wnt but not BMP signaling is involved in the inhibitory action of sclerostin on BMP-stimulated bone formation. J Bone Miner Res 22:19-28
Vesper HW, Audain C, Woolfitt A, Ospina M, Barr J, Robins SP et al (2003) Highperformance liquid chromatography method to analyze free and total urinary pyridinoline and deoxypyridinoline. Anal Biochem 318:204-211
Vestergaard P, Rejnmark L, Weeke J, Mosekilde L (2000) Fracture Risk in Patients Treated for Hyperthyroidism. Thyroid 10:341-348
Wang L, Shao YY, Ballock RT (2007) Thyroid hormone interacts with the Wnt/beta-catenin signaling pathway in the terminal differentiation of growth plate chondrocytes. J Bone Miner Res 22:1988-1995
Winkler DG, Sutherland MK, Geoghegan JC, Yu C, Hayes T, Skonier JE et al (2003) Osteocyte control of bone formation via sclerostin, a novel BMP antagonist. EMBO J 22:6267-6276
Xiaodong L, Ominsky MS, Niu Q-T, Sun N, Daugherty B, D’Agostin D et al (2008) Targeted Deletion of the Sclerostin Gene in Mice Results in Increased Bone Formation vand Bone Strength. J Bone and Miner Res 23:860-869
Xiaofeng Li, Zhang Y, Kang H, Liu W, Liu P, Zhang J et al (2005) Sclerostin binds to LRP5/6 and antagonizes canonical Wnt signaling. J Biol Chem 280:19883-19887
Zaitseva OV, Shandrenko SG, Veliky MM (2015) Biochemical markers of bone collagen type I metabolism. Ukr Biochem J 87:21-32
Acta Biochimica Polonica is an OpenAccess quarterly and publishes four issues a year. All contents are distributed under the Creative Commons Attribution-ShareAlike 4.0 International (CC BY 4.0) license. Everybody may use the content following terms: Attribution — You must give appropriate credit, provide a link to the license, and indicate if changes were made. You may do so in any reasonable manner, but not in any way that suggests the licensor endorses you or your use.
Copyright for all published papers © stays with the authors.
Copyright for the journal: © Polish Biochemical Society.